O’Melveny Worldwide

O’Melveny Represents JACOBIO in the Final 18A Hong Kong IPO of 2020

December 21, 2020


HONG KONG—December 21, 2020—O’Melveny represented JACOBIO PHARMACEUTICALS GROUP CO., LTD. in its IPO and listing today on the Hong Kong Stock Exchange. The IPO offering size was approximately HK$1.35 billion (approximately US$174 million), prior to the exercise of the over-allotment option. Assuming full exercise of the over-allotment option, the offering size will be approximately HK$1.55 billion (approximately US$200 million).

Established in July 2015, Beijing-based Jacobio is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology and other therapies. Jacobio has entered into a global strategic collaboration with AbbVie to develop and commercialize the SHP2 inhibitors of Jacobio on a global basis, including the Core Product of Jacobio.

O’Melveny advised Jacobio on both Hong Kong and United States laws, and was the chief drafter of the prospectus. Goldman Sachs and CICC were the joint sponsors and joint global coordinators.

The O’Melveny team was led by partners Ke Geng and Ke Zhu, and included counsel Yiming Liu, Wendy Kan, and Wei Liu, and associates Xiaoyu Xu, Yiying Wang, Henry Wong, and Qianru Hong.

About O’Melveny

It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com or learn more in our firm at-a-glance, year-end highlights, and on LinkedIn, Twitter, Facebook, Instagram, and YouTube.


Christopher Rieck
O’Melveny & Myers LLP
+1 212 326 2218

Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000